AdaptHealth (AHCO) Expected to Announce Earnings on Tuesday

Key Points

• AdaptHealth (NASDAQ:AHCO) is set to report its Q2 2025 earnings on August 5th, with projections of earnings at $0.15 per share and revenue at $804.97 million.
• The company's shares opened at $9.59 and have a market capitalization of $1.29 billion, showing significant trading activity from institutional investors, with 82.67% of stock owned by such entities.
• Analysts maintain an average buy rating for AdaptHealth, with a price target reduced to $13.40 following assessments by Royal Bank of Canada and Truist Financial.

AdaptHealth (NASDAQ:AHCO - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of $0.15 per share and revenue of $804.97 million for the quarter.

AdaptHealth Stock Down 2.5%

Shares of NASDAQ AHCO traded down $0.22 during midday trading on Friday, reaching $8.75. The company's stock had a trading volume of 1,238,704 shares, compared to its average volume of 1,449,143. The company has a current ratio of 1.29, a quick ratio of 1.07 and a debt-to-equity ratio of 1.25. AdaptHealth has a fifty-two week low of $7.11 and a fifty-two week high of $11.70. The stock has a market capitalization of $1.18 billion, a price-to-earnings ratio of 15.35, a PEG ratio of 0.88 and a beta of 1.63. The stock has a 50 day simple moving average of $9.04 and a 200-day simple moving average of $9.36.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AHCO. Truist Financial lowered their price objective on shares of AdaptHealth from $14.00 to $13.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Royal Bank Of Canada lowered their price objective on shares of AdaptHealth from $14.00 to $13.00 and set an "outperform" rating on the stock in a report on Thursday, May 8th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, AdaptHealth currently has an average rating of "Buy" and a consensus target price of $13.40.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AHCO. Goldman Sachs Group Inc. grew its holdings in shares of AdaptHealth by 32.4% during the first quarter. Goldman Sachs Group Inc. now owns 571,232 shares of the company's stock worth $6,192,000 after purchasing an additional 139,828 shares during the last quarter. Woodline Partners LP bought a new stake in AdaptHealth during the 1st quarter valued at $2,851,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in AdaptHealth by 18.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 233,780 shares of the company's stock worth $2,534,000 after buying an additional 35,879 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of AdaptHealth by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 60,495 shares of the company's stock valued at $656,000 after buying an additional 2,564 shares in the last quarter. Institutional investors and hedge funds own 82.67% of the company's stock.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.